On March 9, the LEAD Coalition (Leaders Engaged on Alzheimer’s Disease), the Alzheimer’s Association, and the Alzheimer’s Impact Movement (AIM) – along with 449 signatories – wrote to Congress in support of the bipartisan Alzheimer’s Screening and Prevention (ASAP) Act (H.R. 6130 / S.3267). The ASAP Act would authorize the Secretary of Health and Human Services to allow Medicare coverage for blood-based dementia screening tests, creating a clear and predictable clinical pathway for access to emerging detection tools.
Please read the House and Senate letters encouraging all Members of Congress to become co-sponsors. (Corresponding letters also were sent to the lead sponsors and current co-sponsors thanking them for their leadership.)